Cerenis Therapeutics raises €40 million in series C financing
Jean-Pierre Garnier appointed as non-executive director to the board
This third round of financing for Cerenis (Series C) will fund Phase II development of the lead Cerenis program, CER-001, an HDL-mimetic for the treatment of cardiovascular disease and to support the development of other new HDL therapies. This round of financing brings the total capital raised to date by the company to €107 million.
Appointment of Jean-Pierre Garnier
Cerenis also announced that Jean-Pierre Garnier, former CEO of GlaxoSmithKline and Pierre Fabre Laboratories, will join the Cerenis Board of Directors as a Non-Executive Director; and will be FSI’s representative on the board.
Most read news
Other news from the department business & finance
These products might interest you
Whatman™ folded filter papers by Cytiva
Whatman folded filter papers
Convenient folded formats speed up your sample preparation
Systec H-Series by Systec
Safe, reproducible and validatable sterilization of liquids, solids and waste
Autoclaves with 65-1580 liters usable space, flexibly expandable for various applications
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.